

Chemicals/Finland, February 19, 2020 Company update

## Improvement potential still exists

Exel's Q4 EBIT failed our estimate due to one-off items. We believe the company remains on an improvement track. Our TP is now EUR 6.75 (6.00), new rating BUY (HOLD).

We continue to expect top line to grow at high single digits Q4 top line, at EUR 26.6m, was flat y/y and a little soft compared to our EUR 27.8m estimate. This was due to Construction & Infrastructure, where Q4 revenue declined by 2% v/v to EUR 12.6m, while we expected EUR 14.3m. Q4 was thus a relatively slow quarter for the segment, as y/y revenue growth had amounted to 12% in Q3. Exel says there have been no changes to e.g. wind energy demand; there can be wide variations in quarterly figures. Industrial Applications' Q4 revenue declined by 1% y/y to EUR 8.5m and so the figure was above our EUR 8.0m estimate. Other Applications' Q4 revenue was in line with our EUR 5.5m estimate. Although Exel's Q4 top line fell short of our estimate only slightly, adj. EBIT was only EUR 1.3m vs our EUR 2.3m estimate. The gap was due to other operating expenses, which were high at EUR 6.4m (had averaged EUR 5.4m in the last few quarters). Exel says the high expenses were due to items like temporary production plant overlap in China as well as certain production-related one-offs. We find no other surprises on the cost side as gross margin remained at a 60% level and employee expense share continued to decline (down by 200bps y/y to 28%). Order intake continued to increase by 9% y/y.

#### Exel guides increasing revenue as well as adj. EBIT for '20

Exel will likely record some EUR 15m capex in '20 due to the production plant investment in Austria and residual payments related to a past Chinese acquisition. Overall, we continue to view Exel's volume outlook favorable. We expect wind energy to provide further strong uplift this year. Exel highlights good volume potential in applications such as cable cores and certain defense-related equipment. With regards to profitability, cost savings measures by themselves should contribute another EUR 1m this year, following the EUR 2m achieved last year.

#### We see more upside as volume outlook remains good

Exel's valuation (ca. 8x EV/EBITDA and 13x EV/EBIT '20e) is still more than 20% below peer multiples. Although we believe some discount is warranted, we see upside from current levels. Our updated TP is EUR 6.75 (6.00), rating now BUY (HOLD).



■ BUY □ HOLD ■ SELL

KEY FIGU	RES									
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR
2018	96.6	2.2	2.3%	-8.7	0.03	119.0	0.8	34.5	-18.3	0.18
2019	103.8	5.1	4.9%	0.7	0.20	32.5	1.0	21.0	0.9	0.18
2020E	109.6	8.7	8.0%	-6.5	0.46	13.2	1.0	12.7	-8.9	0.20
2021E	117.1	9.7	8.3%	5.1	0.51	12.0	0.9	11.2	7.0	0.25
2022E	124.1	10.5	8.5%	8.0	0.58	10.5	0.8	9.7	10.9	0.25
Market cap	o, EURm		73 G	earing 2020E,	0/0		126.6 CAGR	EPS 2019-2	2, %	42.5
Net debt 2	020E, EURm		38 P	rice/book 2020	)E		2.5 CAGR	sales 2019-	22, %	6.1
Enterprise	value, EURm		110 D	ividend yield 2	2020E, %			19.7		
Total asset	s 2020E, EURn	n	99 Ta	ax rate 2020E,	0/0			12.9		
Goodwill 2	020E, EURm		13 E	quity ratio 202	20E, %			1.2		



Chemicals/Finland, February 19, 2020 Company update

#### Estimates and peer group multiples

Exel Composites	2017	2018	Q1/'19	Q2/'19	Q3/'19	Q4/'19	2019	Q1/'20E	Q2/'20E	Q3/'20E	Q4/'20E	2020E	2021E
Industrial Applications	48.2	39.9	9.3	9.5	7.9	8.5	35.3	9.3	9.7	8.1	8.9	36.1	37.9
Construction & Infrastructure	21.3	36.9	11.3	10.9	10.9	12.6	45.7	11.9	12.0	12.0	13.8	49.8	54.8
Other Applications	16.7	19.9	6.5	6.0	4.8	5.5	22.8	6.8	6.3	5.0	5.7	23.7	24.4
Revenue	86.3	96.6	27.1	26.5	23.6	26.6	103.8	27.9	28.0	25.2	28.5	109.6	117.1
change, %	18 %	12 %	26 %	5 %	2 %	0 %	7 %	3 %	6 %	7 %	7 %	6 %	7 %
Gross profit	52.1	57.8	16.1	16.7	13.6	15.9	62.4	16.8	16.8	15.1	17.1	65.7	69.7
-margin, %	60.4 %	59.9 %	59.4 %	63.2 %	<i>57.6</i> %	59.9 %	60.1 %	60.0 %	60.0 %	60.0 %	60.0 %	60.0 %	59.5 %
EBITDA	9.3	7.8	1.8	3.5	2.8	2.6	10.7	3.6	3.6	3.4	3.8	14.3	15.7
-margin, %	10.8 %	8.0 %	6.5 %	13.3 %	11.8 %	9.8 %	10.3 %	12.8 %	12.8 %	13.5 %	13.3 %	13.1 %	13.4 %
Adjusted EBIT	6.3	5.0	2.0	2.2	1.7	1.3	7.2	2.2	2.2	2.0	2.4	8.7	9.7
EBIT	6.1	2.2	0.4	2.1	1.5	1.1	5.1						
-margin, %	7.3 %	5.2 %	7.2 %	8.5 %	7.0 %	4.9 %	6.9 %	7.8 %	7.8 %	7.9 %	8.3 %	8.0 %	8.3 %
-margin (reported), %	7.0 %	2.3 %	1.5 %	8.1 %	6.2 %	4.1 %	4.9 %						

Source: Evli Research

	MCAP		EV/EBITDA			EV/EBIT			EBIT-%	
EXEL COMPOSITES PEER GROUP	MEUR	19	20	21	19	20	21	19	20	21
Gurit Holding	697	10.7x	10.5x	10.8x	14.3x	13.4x	14.0x	9.4 %	10.0 %	9.9 %
Hexagon Composites	648	26.2x	17.6x	13.6x	134.1x	31.4x	21.0x	1.7 %	5.9 %	7.4 %
Hexcel	5689	12.8x	12.6x	11.7x	17.1x	16.9x	15.4x	18.1 %	18.2 %	18.8 %
PolyOne	2206	10.0x	8.3x	7.5x	12.7x	11.1x	9.5x	9.0 %	8.3 %	8.8 %
SGL Carbon	499	9.9x	6.8x	6.4x	18.2x	20.3x	15.5x	4.3 %	3.6 %	4.5 %
TPI Composites	793	10.2x	9.4x	6.8x	32.4x	21.3x	12.0x	1.8 %	3.1 %	5.0 %
Peer Group Average	1755	13.3x	10.9x	9.5x	38.1x	19.1x	14.6x	7.4 %	8.2 %	9.1 %
Peer Group Median	745	10.4x	10.0x	9.2x	17.7x	18.6x	14.7x	6.7 %	7.1 %	8.1 %
Exel Composites (Evli est.)	73	10.0x	7.7x	6.8x	21.0x	12.7x	11.2x	4.9 %	8.0 %	8.3 %
Exel Composites prem./disc. to peer me	rdian	-4 %	-23 %	-25 %	19 %	-32 %	-24 %	-26 %	12 %	2 %

Source FactSet, Evli Research

Chemicals/Finland, February 19, 2020 Company update

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMPTIONS	ASSUMPTIONS FOR WACC	
Current share price	6.12 PV of Free Cash Flow	55 Long-term growth, %	1.5 Risk-free interest rate, %	2.25
DCF share value	7.90 PV of Horizon value	68 WACC, %	8.5 Market risk premium, %	5.8
Share price potential, %	29.2 Unconsolidated equity	0 Spread, %	0.5 Debt risk premium, %	3.3
Maximum value	8.8 Marketable securities	7 Minimum WACC, %	8.0 Equity beta coefficient	1.00
Minimum value	7.2 Debt - dividend	-36 Maximum WACC, %	9.0 Target debt ratio, %	10
Horizon value, %	55.2 Value of stock	94 Nr of shares, Mn	11.9 Effective tax rate, %	21

DCF valuation, EURm	2019	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	Horizon
Net sales	104	110	117	124	132	138	142	146	149	152	154	156
Sales growth, %	7.5	5.6	6.8	6.0	6.0	5.0	3.0	2.5	2.0	2.0	1.5	1.5
Operating income (EBIT)	5	9	10	11	11	12	12	12	13	13	13	13
Operating income margin, %	4.9	8.0	8.3	8.5	8.5	8.5	8.5	8.5	8.5	8.5	8.5	8.5
+ Depreciation+amort.	6	6	6	8	8	7	7	7	6	5	5	
EBITDA	11	14	16	19	19	19	19	19	18	18	19	
- Paid taxes	-2	-2	-2	-2	-3	-3	-3	-3	-3	-3	-3	
- Change in NWC	1	-1	-1	-1	-1	-1	-1	-1	0	0	0	
NWC / Sales, %	14.1	14.2	14.3	14.3	14.4	14.4	14.4	14.5	14.5	14.5	14.5	
+ Change in other liabs	0	0	0	0	0	0	0	0	0	0	0	
- Operative CAPEX	-6	-15	-4	-4	-4	<b>-</b> 5	-5	<b>-</b> 5	-5	-5	-5	
opCAPEX / Sales, %	7.3	15.2	5.1	4.8	4.7	4.6	4.4	4.3	3.6	3.6	3.6	
- Acquisitions	0	0	0	0	0	0	0	0	0	0	0	
+ Divestments	0	0	0	0	0	0	0	0	0	0	0	
- Other items	0	0	0	0	0	0	0	0	0	0	0	
= FCFF	3	-4	8	11	11	11	11	11	10	10	11	152
= Discounted FCFF		-4	7	9	8	7	7	6	5	5	5	68
= DFCF min WACC		-4	7	9	8	7	7	7	6	5	5	76
= DFCF max WACC		-3	7	8	8	7	7	6	5	5	4	61

Chemicals/Finland, February 19, 2020 Company update

#### INTERIM FIGURES

EVLI ESTIMATES, EURm	2019Q1	2019Q2	2019Q3	2019Q4	2019	2020Q1E	2020Q2E	2020Q3E	2020Q4E	2020E	2021E	2022E
· · · · · · · · · · · · · · · · · · ·												
Net sales	27.1	26.5	23.6	26.6	103.8	27.9	28.0	25.2	28.5	109.6	117.1	124.1
EBITDA	1.8	3.4	2.9	2.6	10.7	3.6	3.6	3.4	3.8	14.3	15.8	18.7
EBITDA margin (%)	6.6	13.0	12.1	9.8	10.3	12.7	12.8	13.5	13.3	13.1	13.5	15.0
EBIT	0.4	2.1	1.5	1.1	5.1	2.2	2.2	2.0	2.4	8.7	9.7	10.5
EBIT margin (%)	1.5	7.9	6.4	4.1	4.9	7.7	7.8	7.9	8.4	8.0	8.3	8.5
Net financial items	-0.2	-0.2	0.0	-0.8	-1.2	-0.4	-0.4	-0.4	-0.4	-1.6	-1.6	-1.6
Pre-tax profit	0.2	1.9	1.5	0.3	3.9	1.8	1.8	1.6	2.0	7.1	8.1	9.0
Tax	-0.6	-0.3	-0.7	0.1	-1.5	-0.4	-0.4	-0.4	-0.4	-1.6	-2.0	-2.0
Tax rate (%)	300.0	15.8	46.7	-33.3	38.5	22.9	22.6	25.0	20.0	22.5	24.8	22.5
Net profit	-0.4	1.6	0.8	0.4	2.4	1.4	1.4	1.2	1.6	5.5	6.1	6.9
EPS	-0.03	0.13	0.07	0.03	0.20	0.11	0.12	0.10	0.13	0.46	0.51	0.58
EPS adjusted (diluted no. of shares)	-0.03	0.13	0.07	0.03	0.20	0.11	0.12	0.10	0.13	0.46	0.51	0.58
Dividend per share	0.00	0.00	0.00	0.00	0.18	0.00	0.00	0.00	0.00	0.20	0.25	0.25
SALES, EURm												
Exel Composites	27.1	26.5	23.6	26.6	103.8	27.9	28.0	25.2	28.5	109.6	117.1	124.1
Total	27.1	26.5	23.6	26.6	103.8	27.9	28.0	25.2	28.5	109.6	117.1	124.1
SALES GROWTH, Y/Y %												
Exel Composites	26.0	4.7	2.2	-0.4	7.5	3.0	5.7	6.8	7.1	5.6	6.8	6.0
Total	26.0	4.7	2.2	-0.4	7.5	3.0	5.7	6.8	7.1	5.6	6.8	6.0
EBIT, EURm												
Exel Composites	0.4	2.1	1.5	1.1	5.1	2.2	2.2	2.0	2.4	8.7	9.7	10.5
Total	0.4	2.1	1.5	1.1	5.1	2.2	2.2	2.0	2.4	8.7	9.7	10.5
EBIT margin, %										•		
Exel Composites	1.5	7.9	6.4	4.1	4.9	7.7	7.8	7.9	8.4	8.0	8.3	8.5
Total	1.5	7.9	6.4	4.1	4.9	7.7	7.8	7.9	8.4	8.0	8.3	8.5

Chemicals/Finland, February 19, 2020 Company update

INCOME STATEMENT, EURm	2015	2016	2017	2018	2019	2020E	2021E	2022E
Sales	80.2	73.1	86.3	96.6	103.8	109.6	117.1	124.1
Sales growth (%)	1.1	-8.9	18.1	11.9	7.5	5.6	6.8	6.0
EBITDA	7.3	3.8	9.3	7.7	10.7	14.3	15.8	18.7
EBITDA margin (%)	9.1	5.2	10.8	8.0	10.3	13.1	13.5	15.0
Depreciation	-2.9	-3.2	-3.2	-5.5	-5.6	-5.6	-6.1	-8.1
EBITA	4.4	0.6	6.1	2.2	5.1	8.7	9.7	10.5
Goodwill amortization / writedown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	4.4	0.6	6.1	2.2	5.1	8.7	9.7	10.5
EBIT margin (%)	5.5	0.8	7.1	2.3	4.9	8.0	8.3	8.5
Reported EBIT	4.0	-1.2	6.1	2.2	5.1	8.7	9.7	10.5
EBIT margin (reported) (%)	5.0	-1.6	7.1	2.3	4.9	8.0	8.3	8.5
Net financials	-0.2	-0.1	-0.7	-0.5	-1.2	-1.6	-1.6	-1.6
Pre-tax profit	4.2	0.5	5.4	1.7	3.9	7.1	8.1	9.0
Taxes	-1.4	-0.2	-1.2	-1.3	-1.5	-1.6	-2.0	-2.0
Minority shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit	2.4	-1.4	4.2	0.4	2.4	5.5	6.1	6.9
Cash NRIs	-0.4	-1.8	0.0	0.0	0.0	0.0	0.0	0.0
Non-cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET, EURm								
Assets								
Fixed assets	15	17	16	21	23	33	33	30
Goodwill	10	10	13	13	13	13	13	13
Right of use assets	0	0	0	5	5	5	5	6
Inventory	10	9	12	15	17	18	19	20
Receivables	12	10	15	20	20	21	23	24
Liquid funds	8	7	8	5	7	7	8	8
Total assets	54	54	64	79	85	99	102	103
Liabilities								
Shareholder's equity	31	27	29	26	26	30	33	37
Minority interest	0	0	0	0	0	0	0	0
Convertibles	0	0	0	0	0	0	0	0
Lease liabilities	0	0	0	3	4	5	5	6
Deferred taxes	1	1	0	0	0	0	0	0
Interest bearing debt	8	14	16	30	32	40	37	33
Non-interest bearing current liabilities	14	12	18	18	21	22	24	25
Other interest-free debt	1	1	0	2	2	2	2	2
Total liabilities	54	54	64	79	85	99	102	103
CASH FLOW, EURm								
+ EBITDA	7	4	9	8	11	14	16	19
- Net financial items	0	0	-1	0	-1	-2	-2	-2
- Taxes	-2	0	-1	-2	-2	-2	-2	-2
- Increase in Net Working Capital	-2	1	-3	-4	1	-1	-1	-1
+/- Other	1	-1	1	0	0	0	0	0
= Cash flow from operations	3	3	5	1	8	10	11	14
- Capex	-4	-3	-3	-10	-8	-17	-6	-6
- Acquisitions	0	0	0	0	0	0	0	0
+ Divestments	0	0	0	0	0	0	0	0
= Free cash flow	-1	0	1	-9	1	-6	5	8
+/- New issues/buybacks	1	0	-1	0	0	0	0	0
- Paid dividend	-2	-3	-1	-4	-2	-2	-2	-3
+/- Other	2	2	1	9	3	9	-2	-5
Change in cash	0	-1	0	-3	2	U	0	0

Chemicals/Finland, February 19, 2020 Company update

KEY FIGURES	2016	2017	2018	2019	2020E	2021E	2022E
M-cap	60	78	48	78	73	73	73
Net debt (excl. convertibles)	6	9	28	29	38	35	30
Enterprise value	66	87	76	107	110	108	103
Sales	73	86	97	104	110	117	124
EBITDA	4	9	8	11	14	16	19
EBIT	1	6	2	5	9	10	11
Pre-tax	1	5	2	4	7	8	9
Earnings	0	4	0	2	6	6	7
Equity book value (excl. minorities)	27	29	26	26	30	33	37
Valuation multiples							
EV/sales	0.9	1.0	0.8	1.0	1.0	0.9	0.8
EV/EBITDA	17.3	9.3	9.9	10.0	7.7	6.8	5.5
EV/EBITA	109.9	14.2	34.5	21.0	12.7	11.2	9.7
EV/EBIT	109.9	14.2	34.5	21.0	12.7	11.2	9.7
EV/OCF	21.3	17.7	84.3	12.9	10.8	9.7	7.3
EV/FCFF	-38.8	-28.4	-6.6	32.5	-29.3	13.5	9.5
P/FCFE	0.0	55.8	-5.5	110.9	-11.3	14.4	9.1
P/E		18.6	119.0		13.2	12.0	10.5
r/c P/B	164.3 2.2			32.5	2.5		
•		2.7	1.8	3.0		2.2	2.0
Target EV/EBITDA	0.0	0.0	0.0	0.0	8.2	7.3	5.9
Target EV/EBIT	0.0	0.0	0.0	0.0	13.5	11.9	10.4
Target EV/FCF	0.0	0.0	0.0	0.0	-18.2	22.7	13.8
Target P/B	0.0	0.0	0.0	0.0	2.7	2.4	2.2
Target P/E	0.0	0.0	0.0	0.0	14.5	13.3	11.6
Per share measures							
Number of shares	11,897	11,897	11,897	11,897	11,897	11,897	11,897
Number of shares (diluted)	11,897	11,897	11,897	11,897	11,897	11,897	11,897
EPS	0.03	0.35	0.03	0.20	0.46	0.51	0.58
Operating cash flow per share	0.26	0.41	0.08	0.70	0.86	0.93	1.18
Free cash flow per share	0.00	0.12	-0.73	0.06	-0.54	0.43	0.67
Book value per share	2.24	2.42	2.16	2.21	2.49	2.80	3.14
Dividend per share	0.10	0.30	0.18	0.18	0.20	0.25	0.25
Dividend payout ratio, %	327.2	85.0	535.4	89.2	43.1	49.1	42.8
Dividend yield, %	2.0	4.6	4.5	2.9	3.3	4.1	4.1
FCF yield, %	0.0	1.8	-18.3	0.9	-8.9	7.0	10.9
Efficiency measures							
ROE	1.3	15.2	1.5	9.2	19.7	19.2	19.7
ROE ROCE	1.3 1.8	15.2 14.6	1.5 4.5	9.2 8.6	19.7 12.9	19.2 13.0	19.7 14.1
ROCE							
ROCE Financial ratios	1.8	14.6	4.5	8.6	12.9	13.0	14.1
ROCE Financial ratios Inventories as % of sales	1.8	13.5	4.5 15.7	8.6	12.9	13.0	14.1
ROCE Financial ratios Inventories as % of sales Receivables as % of sales	1.8 12.0 14.0	14.6 13.5 17.1	15.7 20.8	16.3 19.2	12.9 16.3 19.2	13.0 16.3 19.2	14.1 16.3 19.2
ROCE Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales	1.8 12.0 14.0 17.0	14.6 13.5 17.1 21.4	4.5 15.7 20.8 19.2	16.3 19.2 20.2	12.9 16.3 19.2 20.2	13.0 16.3 19.2 20.2	14.1 16.3 19.2 20.2
ROCE Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, %	1.8 12.0 14.0 17.0 9.0	13.5 17.1 21.4 9.3	4.5 15.7 20.8 19.2 16.1	16.3 19.2 20.2 14.1	16.3 19.2 20.2 14.2	16.3 19.2 20.2 14.3	14.1 16.3 19.2 20.2 14.3
ROCE  Financial ratios  Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), %	1.8 12.0 14.0 17.0 9.0 4.2 4.2	13.5 17.1 21.4 9.3 4.1 4.1	15.7 20.8 19.2 16.1 9.9 9.9	16.3 19.2 20.2 14.1 7.3 7.3	12.9 16.3 19.2 20.2 14.2 15.2 15.2	13.0 16.3 19.2 20.2 14.3 5.1 5.1	14.1 16.3 19.2 20.2 14.3 4.8
ROCE Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	12.0 14.0 17.0 9.0 4.2	13.5 17.1 21.4 9.3 4.1	15.7 20.8 19.2 16.1 9.9 9.9 -1.5	16.3 19.2 20.2 14.1 7.3	12.9 16.3 19.2 20.2 14.2 15.2	13.0 16.3 19.2 20.2 14.3 5.1	14.1 16.3 19.2 20.2 14.3 4.8
ROCE Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted	1.8 12.0 14.0 17.0 9.0 4.2 4.2 -0.4 1.6	13.5 17.1 21.4 9.3 4.1 4.1 -0.3 0.9	4.5 15.7 20.8 19.2 16.1 9.9 9.9 -1.5 3.7	8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3 2.7	12.9  16.3 19.2 20.2 14.2 15.2 15.2 -0.3 2.6	13.0  16.3 19.2 20.2 14.3 5.1 5.1 0.5 2.2	14.1 16.3 19.2 20.2 14.3 4.8 4.8 0.6 1.6
ROCE Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	1.8 12.0 14.0 17.0 9.0 4.2 4.2 -0.4	13.5 17.1 21.4 9.3 4.1 4.1 -0.3	15.7 20.8 19.2 16.1 9.9 9.9 -1.5	8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3	12.9  16.3 19.2 20.2 14.2 15.2 15.2 -0.3	13.0 16.3 19.2 20.2 14.3 5.1 5.1 0.5	14.1 16.3 19.2 20.2 14.3 4.8 4.8 0.6

Chemicals/Finland, February 19, 2020 Company update

COMPANY DESCRIPTION: Exel Composites manufactures composites profiles for various demanding, mainly industrial end-use, applications. Exel's customer base includes companies operating in industries such as wind energy, transportation and telecommunications. Exel Composites is one of the largest manufacturers of pultruded composites profiles globally and currently operates eight manufacturing plants on three continents.

INVESTMENT CASE: Our positive view is based on good long-term composites demand outlook, coupled with the fact that Exel Composites' current manufacturing footprint could support annual revenue in the EUR 150m ballpark i.e. there's still plenty of room to improve delivery volumes. Exel's rather high fixed cost base translates to meaningful operating leverage, and thus higher revenues should lead to improving operating margins. The company is also progressing well with its cost savings program. Operating profit could further significantly improve if good execution continues. Recently the wind energy sector has provided great lift for volumes; other attractive applications include e.g. transportation industry profiles.

OWNERSHIP STRUCTURE	SHARES	EURm	0/0
Nordea Bank ABP (Nom. reg.)	2,238,572	13.700	18.8%
Skandinaviska Enskilda Banken AB (Nom. reg.)	761,521	4.661	6.4%
Sijoitusrahasto Taaleritehdas Mikro Markka	650,000	3.978	5.5%
OP-Finland Small Firms Fund	598,259	3.661	5.0%
Danske Invest Finnish Equity Fund	346,650	2.121	2.9%
Phoebus Fund	290,000	1.775	2.4%
Säästöpankki Pienyhtiöt	288,710	1.767	2.4%
Ilmarinen Mutual Pension Insurance Company	242,733	1.486	2.0%
Veritas Pension Insurance Company Ltd.	226,163	1.384	1.9%
Nelimarkka Heikki Antero	222,836	1.364	1.9%
Ten largest	5,865,444	35.897	49%
Residual	6,031,399	36.912	51%
Total	11,896,843	72.809	100%

EARNINGS CALENDAR	
May 06, 2020	Q1 report
July 21, 2020	Q2 report
October 30, 2020	Q3 report
OTHER EVENTS	

CEO: Riku Kytömäki Mäkituvantie 5 01510 Vantaa
CFO: Mikko Kettunen Tel: +358 20 7541 200
IR: Noora Koikkalainen

Chemicals/Finland, February 19, 2020 Company update

#### **DEFINITIONS**

P/E	EPS
Price per share Earnings per share	Profit before extraord. items and taxes- income taxes + minority interest  Number of shares
P/BV	DPS
Price per share Shareholders' equity + taxed provisions per share	Dividend for the financial period per share
Market cap	OCF (Operating cash flow)
Price per share * Number of shares	EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments
EV (Enterprise value)	FCF (Free cash flow)
Market cap + net debt + minority interest at market value – share of associated companies at market value	Operating cash flow – operative CAPEX – acquisitions + divestments
EV/Sales	FCF yield, %
Enterprise value Sales	Free cash flow  Market cap
EV/EBITDA	Operative CAPEX/sales
Enterprise value Earnings before interest, tax, depreciation and amortization	Capital expenditure – divestments – acquisitions Sales
EV/EBIT	Net working capital
Enterprise value Operating profit	Current assets – current liabilities
Net debt	Capital employed/Share
Interest bearing debt – financial assets	Total assets – non-interest bearing debt  Number of shares
Total assets	Gearing
Balance sheet total	<u>Net debt</u> Equity
Div yield, %	Debt/Equity, %
Dividend per share Price per share	Interest bearing debt Shareholders' equity + minority interest + taxed provisions
Payout ratio, %	Equity ratio, %
Total dividends  Earnings before extraordinary items and taxes – income taxes + minority interest	Shareholders' equity + minority interest + taxed provisions  Total assets – interest-free loans
ROCE, %	CAGR, %
Profit before extraordinary items + interest expenses+ other financial costs  Balance sheet total - non-interest bearing debt (average)	Cumulative annual growth rate = Average growth per year
ROE, %	
Profit before extraordinary items and taxes – income taxes  Shareholder's equity + minority interest + taxed provisions (average)	

Chemicals/Finland, February 19, 2020 Company update

#### Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at <u>Analysts' recommendations and ratings revisions</u>.

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 timer per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 1st of February 2019. If recommendation is not given, it is not mentioned here.

#### Name(s) of the analyst(s): Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Bank Plc. Production of the investment recommendation has been concluded on [19.2.2020, 8:55]. This report has been published on [19.2.2020, 9:10].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or EVIi. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment

#### **EVLI EQUITY RESEARCH**

## **EXEL COMPOSITES**

Chemicals/Finland, February 19, 2020 Company update

Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Bank Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Bank Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli Bank is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Bank Plc is supervised by the Finnish Financial Supervision Authority.

Chemicals/Finland, February 19, 2020 Company update

# Contact information SALES, TRADING AND RESEARCH

Equity Sales		Trading		ETFs and Derivatives	
Ari Laine Lauri Ahokanto Niclas Henelius	+358 9 4766 9115 +358 9 4766 9117 +358 9 4766 9116	Lauri Vehkaluoto (Head) Pasi Väisänen Antti Kässi Miika Roankanen	+358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120	Joachim Dannberg Kimmo Lilja	+358 9 4766 9123 +358 9 4766 9130
Structured Investments		Equity Research			
Heikki Savijoki Aki Lakkisto	+358 9 4766 9726 +358 9 4766 9123	Jonas Forslund Joonas Ilvonen Jerker Salokivi Anna-Liisa Rissanen	+358 9 4766 9314 +358 44 430 9071 +358 9 4766 9149 +358 40 157 9919		
Evli Investment Solutions					
Johannes Asuja Markku Reinikainen	+358 9 4766 9205 +358 9 4766 9669				



EVLI BANK PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Fax +358 9 634 382
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI BANK PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000 Fax +46 (0)8 407 8001